Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within  weeks prior to registration (resting ejection fraction >= % or >= % increase with exercise), shortening fraction by echocardiogram >= %, or to within the normal range of values for the institution
Patients must have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within  days prior to registration with a cardiac ejection fraction >= %
Left ventricular ejection fraction >= %, as determined by multigated acquisition (MUGA) or echocardiogram within  days prior to protocol registration
Patients must have left ventricular ejection fraction (LVEF) >=  as measured by echocardiogram or multigated acquisition scan (MUGA)
Patients with an ejection fraction < % assessed by multigated acquisition scan (MUGA) or echocardiogram (ECHO) scan within  days of day 
Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within  days prior to first dose of study drug
Participants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to % within  days prior to the first dose of study drug.
Left ventricular ejection fraction (LVEF) >= % by -dimensional (D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan; timeline: within  weeks prior to enrollment
Prior or current cardiomyopathy including but not limited to the following: known hypertrophic cardiomyopathy, known arrhythmogenic right ventricular cardiomyopathy, previous moderate or severe impairment of left ventricular systolic function (left ventricular ejection fraction [LVEF] < % on echocardiography or equivalent on multigated acquisition scan [MuGA]) even if full recovery has occurred
Left ventricular ejection fraction; LVEF >= % (by echocardiogram or multigated acquisition scan [MUGA] testing)
For Part F (LY + trastuzumab):The participant must have received at least  chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with trastuzumab. The participant must have an estimated left ventricular ejection fraction within the normal range by either echocardiogram or multigated acquisition (MUGA) scan
Patients with symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) my multigated acquisition scan (MUGA) or echocardiogram (ECHO) of =< % are not eligible
Left ventricular ejection fraction (LVEF) >= % (determined by echocardiogram or multigated acquisition scan) within  days of treatment
Left ventricular ejection fraction (LVEF) ? % by echocardiogram (echo) or multigated acquisition (MUGA) scan within  days before day  of study
Have a left ventricular ejection fraction (LVEF) >% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
On echocardiogram, documented left ventricular ejection fraction > %; patients may instead have a multigated acquisition (MUGA) scan instead of transthoracic echocardiogram (TTE).
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Left ventricular ejection fraction (LVEF) >= % as determined by echocardiogram or multigated acquisition scan (MUGA)
Left ventricular cardiac ejection fraction of ?% by echocardiogram or multigated acquisition (MUGA) scan
Left ventricular ejection fraction >= % by multigated acquisition scan (MUGA) or echocardiogram
Shortening fraction > % by echocardiogram or Ejection Fraction of >  % by multigated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) must be equal to or greater than %, as measured by multigated acquisition (MUGA) scan or echocardiogram
Ejection fraction measured by echocardiogram or multigated acquisition (MUGA) >= %
Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) done only in subjects with prior doxorubicin exposure. The test must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Ejection fraction < % on screening echocardiography (ECHO) or multigated acquisition scan (MUGA).
Cardiac ejection fraction within institutional normal limits by either multigated acquisition scan (MUGA) or echocardiogram (ECHO) at baseline
If the participant is to be enrolled in the doxorubicin combination arm, a left ventricular dysfunction (LVEF < %) or shortening fraction of <% by echocardiogram (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not both).
Must be hemodynamically stable at the time of ETL-ARTEMIS T cell administration and have left ventricular ejection fraction (LVEF) ? % confirmed by echocardiogram or multigated acquisition scan (MUGA) scan
Shortening fraction >= % by echocardiogram OR ejection fraction of >=  % by multigated acquisition (MUGA)
Within  weeks before enrollment: Left ventricular ejection fraction (LVEF) > % by multigated acquisition (MUGA) or rest echocardiogram (ECHO)
Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) of >= % as assessed by echocardiogram or multigated acquisition (MUGA) scan, or LVEF of -% and clearance by a cardiologist
Left ventricular ejection fraction (LVEF) ? % at rest (multigated acquisition [MUGA] scan or echocardiogram [Echo])
Has left ventricular ejection fraction (LVEF) < % by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
Shortening fraction >= % by echocardiogram or ejection fraction of >=  % by multigated acquisition (MUGA)
Cardiac echocardiogram, stress test, or multigated acquisition (MUGA) within past  months with demonstrated left ventricular ejection fraction (LVEF) > %
Left ventricular ejection fraction >= % measured by multigated acquisition (MUGA) scan or echocardiogram
If a patient has received anthracycline chemotherapy after prior enrollment on PLAT-, they must have an echocardiogram to demonstrate shortening fraction > % or multigated acquisition scan (MUGA) to demonstrate ejection fraction of > %; the echocardiogram or MUGA can be done at any time following the anthracycline (does NOT need to be within  hours of the T cell infusion)
(For cohort B): Baseline multigated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= % within  weeks prior to initiation of NACT
Impaired cardiac function (left ventricular ejection fraction [LVEF] < %) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) >= %, assessed within  months prior to registration, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
Left ventricular ejection fraction (LVEF) >= % by transthoracic echocardiogram or multigated acquisition scan (MUGA)
Patients have left ventricular ejection fraction (LVEF) >= % by multigated acquisition scan (MUGA) or echocardiogram before study randomization
Baseline left ventricular ejection fraction of at least % by multigated acquisition (MUGA) or echocardiography (ECHO)
Left ventricular ejection fraction (LVEF) at rest >= %; for patients aged <  years, shortening fraction (SF) >= % by echocardiogram or LVEF by multigated acquisition scan (MUGA) may be used
Left ventricular ejection fraction (LVEF) < % as determined by multigated acquisition (MUGA) scan or electrocardiogram (ECHO), or uncontrolled hypertension (refer to World Health Organization-International Society of Hypertension [WHO-ISH] guidelines)
Adequate cardiac function as defined by the following:\r\n* Left ventricular ejection fraction (LVEF) >= % as determined by a multigated acquisition (MUGA) scan or echocardiogram\r\n* Corrected QT interval (QTc) interval =<  ms (preferably the mean from triplicate electrocardiogram [ECGs])
Ejection fraction of > % by multigated acquisition (MUGA) or echocardiogram
Left ventricular ejection fraction (by transthoracic echocardiography [TTE], multigated acquisition scan [MUGA] or cardiac magnetic resonance imaging [MRI]) sufficient to safely administer mitoxantrone as determined by the treating physician
Ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) >= %
Cardiac ejection fraction >= % (by either echocardiogram [ECHO] or multigated acquisition [MUGA])
If prior history of ischemic heart disease or exposure to  mg/m^ of doxorubicin, patients must have a measured ejection fraction (either by multigated acquisition scan [MUGA], echocardiogram [ECHO], stress test, or ventriculography) of at least %
Shortening fraction > % by echocardiogram or an ejection fraction > % by multigated acquisition scan (MUGA)
Cardiac ejection fraction > % (for HER+ patients) as assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Left ventricular ejection fraction (LVEF) of % or above, by multigated acquisition scan (MUGA) or echocardiogram
If the research participant is to undergo leukapheresis, he/she must have ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) > % (within  weeks of time of screening)
Ejection fraction >=% by transthoracic echocardiogram or radionuclide ventriculogram, i.e. multigated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) greater than or equal to % as determined by a multigated acquisition (MUGA) scan or echocardiogram (Phase II only)
Patients must have adequate cardiac function (left ventricular ejection fraction [LVEF]) >= % as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (EF) > % by echocardiogram, multigated acquisition scan (MUGA), or cardiac magnetic resonance (MR)
No cardiac (left ventricular ejection fraction [LVEF] > % by multigated acquisition scan [MUGA] or three-dimensional echocardiography [TTE]; if LVEF > % but < % by MUGA or TTE MUST HAVE cardiology evaluation and clearance for ASCT)
Left ventricular ejection fraction (LVEF) >= % as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) or other similar cardia imaging performed within  month of treatment
Have a left ventricular ejection fraction (LVEF) >% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Patients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram) < % are excluded
Adequate cardiac function (left ventricular ejection fraction [LVEF] >= %) as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan performed within  month of treatment
Left ventricular ejection fraction (LVEF) >= % measured by multigated acquisition (MUGA) scan, echo, or stress test study with myocardial perfusion imaging
Left ventricular ejection fraction (LVEF) >= % as determined by a multigated acquisition (MUGA) scan or echocardiogram, and QTc interval =< ms
To be performed within  days prior to day  of protocol therapy: Left ventricular ejection fraction >= % as determined by multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) >= % calculated by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Ejection fraction (EF) >= % by multigated acquisition (MUGA) or echocardiography (ECHO) within  weeks prior to first dose of study treatment
Adequate cardiac function:\r\n* Left ventricular ejection fraction (LVEF) >= % as determined by multigated acquisition (MUGA) scan or echocardiogram (echo)\r\n* Corrected QT (QTc) interval =<  ms
Left ventricular ejection fraction (LVEF) >= % at rest (multigated acquisition scan [MUGA] or echocardiogram [Echo])
Patients must have multigated acquisition (MUGA)/echocardiogram performed within  days prior to sub-study registration
Ejection fraction (EF) measured by two-dimensional echocardiogram (D-ECHO) or multigated acquisition scan (MUGA) scan of >= %
Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= % by echocardiogram (ECHO) or multigated acquisition scan (MUGA); same method as used at baseline must be use throughout the study, ECHO is the preferred method
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multigated acquisition (MUGA) > %
Left ventricular ejection fraction >= % by multigated acquisition scan (MUGA) or echocardiogram (ECHO), fractional shortening >= % by ECHO
Left ventricular ejection fraction at or above institutional lower limit of normal (obtained within  weeks of registration by multigated acquisition [MUGA] scan or echocardiogram; the same test performed at baseline should be repeated after every  cycles of therapy)
Cardiac ejection fraction at or above the lower limit of normal as measured by multigated radionuclide angiography (MUGA) scans or echocardiogram documented =<  months prior to registration
Patients must have a left ventricular ejection fraction >= lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Have left ventricular ejection fraction by multigated acquisition scan (MUGA) scan or D-ECHO within normal limits for the institution
Left ventricular ejection fraction >= lower limit of normal as assessed by echocardiogram or multigated acquisition scan
Patients who received prior therapy with anthracyclines should have a baseline multigated acquisition scan (MUGA) or echocardiogram (echo) with a normal ejection fraction within  days prior to randomization
left ventricular ejection fraction (LVEF) < % as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO).
Patients must have a left ventricular ejection fraction (LVEF) >= % by (either multigated acquisition [MUGA] or -dimensional [-D] echocardiogram) within  days of registration
Left ventricular ejection fraction (LVEF) >= % as confirmed by echocardiogram (ECHO)/multigated acquisition (MUGA)
Patient must have adequate cardiac function (left ventricular ejection fraction [LVEF] >= % as determined by a multigated acquisition [MUGA] scan or echocardiogram; and corrected QT [QTc] interval =<  ms by Fridericias formula [QTcF])
Cardiac left ventricular function with resting ejection fraction >% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
Patients older than  years of age should have left ventricular ejection fraction within ULN by multigated acquisition (MUGA) or -dimensional (D) echocardiogram
Left ventricular ejection fraction (LVEF) < % as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) defined by multigated acquisition (MUGA) or echocardiogram which is below the institutional lower limit of normal prior to starting study treatment
Has a left ventricular ejection fraction (LVEF) within the normal institutional range (or >= %) based on an echocardiogram (ECHO) or multigated acquisition scan (MUGA), completed within  weeks prior to day one of treatment
Baseline Left ventricular ejection fraction (LVEF) >=% as measured by Echocardiogram (ECHO) or Multigated acquisition (MUGA) and above the testing institution's lower limit of normal
Left ventricular ejection fraction (LVEF) >= % on -dimentional (-D) transthoracic echocardiogram (ECHO); multigated acquisition scan (MUGA) is acceptable
Adequate cardiac function defined as left ventricular ejection fraction (LVEF) >= %\r\n* NOTE: -dimensional (-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation\r\n* Multigated acquisition scan (MUGA) is acceptable if ECHO is not available
Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within  weeks prior to first dose of study drug.
Have a -lead electrocardiogram (ECG) and echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed by the investigator or other qualified person to evaluate cardiac function prior to enrollment in the study
Left ventricular ejection fraction >= %, as determined by radionuclide ventriculogram (RVG) (multigated acquisition [MUGA]) or echocardiogram (ECHO) within  days prior to initiation of protocol therapy
Normal left ventricular ejection fraction on multigated acquisition scan (MUGA) or echocardiogram within the past  year prior to registration for patients with history of congestive heart failure and/or coronary disease requiring medications other than aspirin, or known prior exposure to anthracycline chemotherapy
Ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) of >= % performed
Adequate cardiac function (left ventricular ejection fraction [LVEF] > %) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within  month of treatment
Ejection fraction >= % as determined by transthoracic echocardiogram or multigated acquisition scan (MUGA)
Cardiac ejection fraction >= lower limit of normal as determined by -dimensional (D) echocardiogram (echo) or multigated acquisition (MUGA) scan according to institutional standards
Cardiac ejection fraction, as assessed by either multigated acquisition (MUGA) scan or echocardiogram, greater than or equal to %, within  days prior to registration
Left ventricle ejection fraction (LVEF) >= %; -dimensional (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition scan (MUGA) is acceptable if ECHO is not available
Left ventricular ejection fraction >= the lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= % (as assessed by echocardiography [ECHO] or multigated acquisition [MUGA]) documented within  weeks prior to first dose of study treatment
Left ventricular ejection fraction > % by either multigated acquisition scan (MUGA) or -dimensional (-D) echocardiogram (echo), obtained within  days of enrollment; patients who have a prior cumulative anthracycline dose greater than  mg/m^ will also have a cardiology consult to determine if further anthracycline administration is an absolute contraindication in patients who may require induction chemotherapy with EPOCH-F
Ejection fraction (EF) of at least >= % by multigated acquisition (MUGA) or echocardiography (ECHO)
Left ventricular ejection fraction (LVEF) >= % as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction by multigated acquisition scan (MUGA) or echocardiogram >= % for patients with triple negative breast cancer; >= upper limit of institutional normal for patient with HR+ breast cancer within  days of treatment initiation
Left ventricular ejection fraction =< % as demonstrated by echocardiogram or multigated acquisition scan (MUGA)
Patients with left ventricular ejection fraction < % on echocardiogram or multigated acquisition scan will be excluded
Left ventricular ejection fraction (LVEF) >=  % (by multigated acquisition scan [MUGA] or echocardiography)
Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= %
Cardiac ejection fraction >= % (by either cardiac echocardiogram [echo] or multigated acquisition [MUGA] scan); documentation of recent (=<  months from screening) outside reports is acceptable
Adequate organ function defined by the screening laboratory inclusion listed below and Left Ventricular Ejection Fraction (LVEF) ? % confirmed by ECHO or multigated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= % (multigated acquisition scan [MUGA] or echocardiogram)
All patients must have an echo or multigated acquisition (MUGA) scan showing ejection fraction (EF) > % and normal troponin and creatine kinase MB (CK MB) performed within  days of starting treatment
Cardiac ejection fraction >= %, as measured by echocardiography (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= % as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) > % (by echocardiogram [ECHO] or multigated acquisition scan [MUGA])
Left ventricular ejection fraction (LVEF) >= % by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= % within  days before cycle  day ; -dimensional (-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition (MUGA) is acceptable if ECHO is not available
Patients must have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal within one month prior to start of study.
All patients must have an left ventricular ejection fraction (LVEF) measurement of at least % by echocardiogram (ECHO) or multigated acquisition scan (MUGA) (if clinically indicated) within  days prior to registration; the method used for LVEF assessment in an individual subject must be the same throughout the trial
Left ventricular ejection fraction > % on echocardiography or multigated acquisition (ECHO/MUGA) scan
Left ventricular ejection fraction (LVEF) >= % as determined by a multigated acquisition (MUGA) scan or echocardiogram (ECHO)
Uncontrolled or severe cardiovascular disease or left ventricular ejection fraction < % as determined by echocardiogram or multigated acquisition scan (MUGA)
A resting ejection fraction of % or greater which increases with exercise as demonstrated by resting/exercise multigated acquisition (MUGA) or ejection fraction of % or greater by echocardiogram
Left ventricular ejection fraction (LVEF) greater or equal to % at baseline as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= % by multigated acquisition scan (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= % by multigated acquisition (MUGA) scan or echocardiogram
Has left ventricular ejection fraction (LVEF) < % by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
